Prezista (Darunavir, TMC114)

See also: Drug Interactions | Medication Side Effects | All HIV Medications

Brand Name:	Prezista
Generic Name:	darunavir, TMC114
Adult Single Dose:	Two 300 mg tablets twice daily taken with ritonavir 100 mg twice daily.
Food & Liquid Restrictions:	Take with food.
Drug Class:	PI

The Basics

An Overview of Prezista (Darunavir, TMC114) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health
Darunavir (Prezista) (July 31, 2009)
To read PDF, click here
From AIDS InfoNet
Prezista (March/April 2009)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
Patient Information About Prezista (Darunavir, TMC114) (PDF) (December 2008)
From Tibotec Therapeutics
Prezista (Darunavir, TMC-114) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
An Interview With Cal Cohen, M.D., a Lead Investigator of the Darunavir (TMC114, Prezista) POWER Trials (June 28, 2006)
Dr. Cohen discusses TMC114's uses, adverse effects and other considerations.
Prezista Approval (June 23, 2006)
From U.S. Food and Drug Administration

News

Prezista Now Available for Pediatric Patients Six Years of Age and Older as Part of HIV Combination Therapy (February 11, 2009)
From Tibotec Therapeutics
New 75 mg Prezista Tablet and Corresponding Pediatric Dosing Information Approved (December 18, 2008)
From U.S. Food and Drug Administration
HIV/AIDS Update - Important information about Prezista (darunavir) (October 22, 2008)
From U.S. Food and Drug Administration
Updates to Prezista (Darunavir) Tablets Labeling (March 11, 2008)
From U.S. Food and Drug Administration
"Dear Healthcare Professional" Letter: New Prescribing Information for Prezista (Darunavir) (March 2008)
Labeling has been updated to include warnings regarding hepatotoxicity.
From Tibotec Therapeutics
New 600-mg Tablet Strength for Prezista (Darunavir) (February 26, 2008)
From U.S. Food and Drug Administration
A Drug Pricing Victory: Tibotec Prices Prezista at Far Below Cost of Reyataz, Fuzeon (June 30, 2006)
Tibotec Announces U.S. Expanded Access Program for TMC114 (October 26, 2005)
[Archived Article]
Though not yet FDA approved, TMC114 is now available for some with multidrug resistance.
From Tibotec Therapeutics
TMC114 Expanded Access Program for People Living With HIV to Begin Enrollment in Autumn of 2005 (June 14, 2005)
[Archived Article]
From Tibotec Therapeutics

Research

Boosted Darunavir Monotherapy Works Well in Two Studies (July 23, 2009)
Ritonavir-boosted darunavir alone maintains HIV suppression in most patients who achieved an undetectable viral load on combination antiretroviral therapy, according to two studies.
From aidsmap.com
Adding Etravirine to Prezista Improves Anti-HIV Activity, Studies Show (July 6, 2007)
From aidsmap.com
Darunavir Superior to Lopinavir in 48-Week Study in Treatment-Experienced Patients (July 6, 2007)
From aidsmap.com
GRACE Under Pressure (December 2006)
To read PDF, click here
In TAGline, from Treatment Action Group
48-Week TMC114 + Ritonavir Data Set New Bar for Efficacy in Triple-Class-Experienced Patients (August 15, 2006)
In XVI International AIDS Conference
TMC114 Significantly Outperforms Control Protease Inhibitors in Triple-Class-Experienced Patients, Even in Absence of Enfuvirtide (July 27, 2005)
[Archived Article]
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
New Protease Inhibitor TMC-114: Preliminary 24-Week Late Breaker Results of the Phase II Trial (March/April 2005)
[Archived Article]
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
TMC-114 Sets a New Standard in Salvage Therapy Trials (February 25, 2005)
[Archived Article]
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Research Updates on Tipranavir, TMC-114 and TMC-125 (December 2004)
[Archived Article]
A review of the tipranavir RESIST studies, a note on potential tipranavir pricing, and a critical look at two developing rescue drugs.
In TAGline, from Treatment Action Group
Anti-HIV Therapy Update (July 2004)
[Archived Article]
A quick briefing on tipranavir, TMC-114, capravirine and D-D4FC.
To read PDF, click here
In Project Inform Perspective, from Project Inform
Initial Data on TMC114 in Multiple PI-Experienced Patients (July 16, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO